PIEDMONT PHARMACEUTICALS APPOINTS MICHAEL KELLY AS CHIEF FINANCIAL OFFICER

PIEDMONT PHARMACEUTICALS APPOINTS MICHAEL KELLY AS CHIEF FINANCIAL OFFICER

(Greensboro, NC)

July 15, 2009 - Piedmont Pharmaceuticals LLC, a specialty

pharmaceutical company focused on parasitology and drug delivery systems for human

and companion animal use, has appointed Michael Kelly as Chief Financial Officer.

Kelly was most recently Chief Financial Officer of Global Manufacturing for Novartis

Animal Health and before that, CFO of the Novartis Animal Health North American

region. During his tenure as CFO, sales and profitability growth in the USA exceeded

20% on an annual basis. He joined the Novartis legacy company Ciba-Geigy in 1985

upon graduation from Harvard Business School and spent four years in Basle,

Switzerland in business development followed by a number of product management,

strategic planning and senior finance positions with Ciba and later, Novartis Animal

Health.

"Michael's financial acumen, his record of achievement with Ciba and Novartis, and his

knowledge of the global animal health industry is a tremendous asset to Piedmont and our

leadership team," said Roland Johnson, CEO of Piedmont Pharmaceuticals.

Kelly recently served on the North Carolina State Biotechnology Initiative (Growing

NC's AgBiotech Landscape) and is the Committee Chair of Boy Scout Troop 139 of Oak

Ridge, NC. He and his wife Donna have two children and a farm full of horses and

companion animals.

***

About Piedmont Pharmaceuticals LLC

Piedmont Pharmaceuticals LLC is a Greensboro, N.C.-based specialty pharmaceutical

company focused on animal health and human therapeutics with expertise in parasitology

and drug delivery systems. The company's currently commercialized products and

advanced development program leverage unique modes of action and proprietary delivery

technologies. Piedmont Pharmaceuticals develops new formulations, uses and delivery

vehicles for known active pharmaceutical compounds for both the companion animal and

human health markets.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.